Contact Us
		Ordering Info For ordering please see biovitrum.com E-mail Us Information: medical.info@biovitrum.com Call Us Please note that all Toll Free Numbers listed does not work across all mobile phone providers. Alternative numbers are therefore listed below. Australia 1-800-086468 Austria +800 386 587 21 Belgium +800 386 587 21 Canada 866-773-5274 Cyprus +800 386 587 21 Czech Republic +800 386 587 21 Denmark +800 386 587 21 Estonia +800 386 587 21 Finland +800 386 587 21 France +800 386 587 21 Germany +800 386 587 21 Greece +800 386 587 21 Hungary +800 386 587 21 Iceland +800 386 587 21 Ireland +800 386 587 21 Italy +800 386 587 21 Japan +800 386 587 21 Latvia +800 386 587 21 Lithuania +800 386 587 21 Luxembourg +800 386 587 21 Netherlands +800 386 587 21 New Zealand 0800-446286 Norway +800 386 587 21 Poland +800 386 587 21 Portugal +800 386 587 21 Slovakia +800 386 587 21 Slovenia +800 386 587 21 Spain +800 386 587 21 Sweden +46 8 697 20 00* or +800 386 587 21 Switzerland +800 386 587 21 UK +800 386 587 21 USA 866-773-5274 *Not toll free Alternative Numbers Select language. Please note that these are not Toll Free Numbers! English: +41 61 564 13 28 German: +41 61 564 13 29 French: +41 61 564 13 30 Italian: +41 61 564 13 31 Spanish: +41 61 564 13 32
	Kineret® (anakinra) is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs). Kineret® can be used alone or in combination with DMARDs other than tumor necrosis factor (TNF) blocking agents. In clinical trials, there was a risk of serious infections (2% in Kineret® patients vs. less than 1% in placebo patients). Kineret® should be discontinued if a patient develops an infection, however most patients can continue taking Kineret® after their infection resolves. Kineret® should not be used with TNF-blocking agents such as etanercept, adalimumab, and infliximab. A 7% rate of serious infections was observed in a 24-week study of concurrent administration of Kineret® and etanercept. Kineret® is contraindicated in patients with known hypersensitivity to E coli-derived proteins, Kineret®, or any components of the product. The most common side effect in clinical trials was injection site reaction, which was usually mild and characterized by redness, swelling, and pain. Biovitrum.com | Site Map © 2008 Biovitrum Ab (publ). All rights reserved. This site is intended for U.S. audiences only.